PTX prescient therapeutics limited

Ann: March 2021 Quarterly Update and Appendix 4C, page-6

  1. 2,315 Posts.
    lightbulb Created with Sketch. 648
    Indeed.
    $60m MC seems to imply a huge upside potential, especially Prescient is putting more effort and focus on CTE, the Cell Therapy Enhancement programme, which is well sought after by the mkt.

    IMHO to double MC to $120m doesn’t seem to be a distant possibility, if we look at other peers in similar biotech startups...
    So, SP 20c I m hoping one day in the near future

    As usual, best of luck to patients + LTSH!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
4.3¢
Change
0.001(2.38%)
Mkt cap ! $34.62M
Open High Low Value Volume
4.2¢ 4.3¢ 4.1¢ $85.86K 2.043M

Buyers (Bids)

No. Vol. Price($)
1 85000 4.2¢
 

Sellers (Offers)

Price($) Vol. No.
4.4¢ 288000 3
View Market Depth
Last trade - 15.58pm 14/07/2025 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.